This signature is associated with heterozygous loss and deletion of RB1, loss of CDKN2A, amplification of CCND1, and amplification of CDK4, and is prognostic in ACC, LGG, KIRK, and SARC. This evidence concerns the gene CDKN2A and adrenal cortex carcinoma.